Elevance Health Lifts 2026 Profit View to $27.00 Per Share
ELV sits 61% above its 52-week low of $273.71.
Summary
Elevance Health raised its full-year 2026 adjusted EPS guidance to $27.00, up from a prior view that was already lifted after strong Q1 results. The company reported Q2 2026 revenue of $49.8 billion and adjusted diluted EPS of $7.45, beating estimates, driven by CarelonRx growth and better medical cost management. This follows the April report where adjusted EPS of $12.58 crushed estimates, though a $935 million Medicare Advantage accrual was a notable headwind. The new target signals sustained momentum, and the stock is trading near its 52-week high, potentially fueling further upside. The magnitude of the raise relative to the prior outlook will be key, with analyst revisions and management commentary on the earnings call to gauge whether the $27.00 figure embeds conservative assumptions or reflects accelerating fundamentals.
At the time of this announcement, ELV was trading at $439.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $92.7B. The 52-week trading range was $273.71 to $436.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.